Under this agreement,
LymphMark is a 20-gene signature that classifies cell-of-origin subtypes of Diffuse Large B-cell Lymphoma (DLBCL) tumors. The initial indication for the LymphMark assay is expected to be a potential companion diagnostic to aid in identifying DLBCL patients for treatment. The LymphMark assay is based on the Lymph2Cx gene signature that was originally developed by the
The LymphMark assay was used to select patients in a Phase III clinical trial. The LymphMark assay is being evaluated in more than 40 research studies that are being conducted with 23 companies.
"Through this collaboration, we will work closely with Riken Genesis to launch novel diagnostic products on the nCounter platform that have the potential to guide decision making in the Japanese oncology community," said
"We are pleased to partner with
For more information, please visit www.nanostring.com.
RIKEN GENESIS, founded in
For more information, please visit https://rikengenesis.jp/
Forward-Looking Statements -
This news release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 and the Private Securities Litigation Reform Act of 1995. These forward-looking statements include statements regarding the potential of LymphMark as a companion diagnostic
to aid in identifying DLBCL patients for treatment. Such statements are based on current assumptions that involve risks and uncertainties that could cause actual outcomes and results to differ materially. These risks and uncertainties, many of which are beyond our control, include market acceptance of our products; delays or denials of regulatory approvals or clearances for products; the impact of competition; the impact of expanded sales, marketing, product development on operating expenses; delays or other unforeseen problems with respect to manufacturing and product development; adverse conditions in the general domestic and global economic markets; as well as the other risks set forth in the company's filings with the
For more information, please visit http://www.nanostring.com.
Vice President, Investor Relations & Corporate Communications
General Manager, Sales & Marketing
News Provided by Acquire Media